One Researcher at L'Oréal Spent 1999 Figuring Out How to Target Eye Bags, Dark Circles, and Redness With a Single Formula

Cosmetic Archaeology is a series about reading expired cosmetic patents. In the first installment I traced the lineage of sensitive-skin formulation through a 1994 Kao patent. In the second I walked through how to navigate Google Patents and J-PlatPat for cosmetic research. This time: eye care.

I have had rosacea on my jaw for nearly ten years. Most commercial cosmetics fail on my skin. That's the reason I started digging into expired patents — the formulas are public, the concentrations are precise, and the design reasoning is written down.

Conclusion First

In 1999, a L'Oréal researcher named Béatrice Renault documented a "surprising synergistic effect" between dextran sulfate and escin — two ingredients that, when combined, reduced edema scores beyond what simple addition would predict. The patent (US6562355B1) expired in October 2020. All six formulation examples are now public. By 2026, escin derivatives appear in eye care lines from Clarins and others; a 2018 peer-reviewed paper (PMID: 30233225) confirmed dextran sulfate's vascular anti-inflammatory mechanism. The 1999 hypothesis aged well.

Primary Source: L'Oréal US6562355B1

• Patent title: Comixture of dextran sulfate/escin for treating skin redness/edema and/or sensitive skin
• Inventor: Béatrice Renault (single inventor)
• Assignee: Société L'Oréal S.A. (France)
• Priority date: October 8, 1999 (France)
• US filing date: October 10, 2000
• Publication date: May 13, 2003
• Expiration: October 10, 2020 (20-year term, now public domain)
• Corresponding patents: EP1090629B1 (Europe), JP3737026B2 (Japan)

The stated target is explicit: "redness and/or edema around the eyes" and specifically "bags and/or dark rings around the eyes." One formula designed to address all of it.

Why Two Ingredients?

The patent's core claim is that mixing dextran sulfate and escin produces results that exceed the sum of each ingredient used alone. The language in the filing: "surprising synergistic effect."

L'Oréal measured edema scores experimentally:

• Escin alone → measurable improvement
• Dextran sulfate alone → measurable improvement
• The combination → improvement exceeding simple addition

Here is what each ingredient does.

Escin

Escin is a saponin extracted from horse chestnut seeds (Aesculus hippocastanum). Its structure: glucuronic acid linked to glucose and xylose. The patent notes that both natural and synthetic escin qualify.

The mechanism: escin strengthens capillary walls and reduces their permeability. This limits vasodilation — the blood vessel widening that produces visible redness and fluid accumulation. Think of it as a structural reinforcing agent for small blood vessels.

Dextran Sulfate

Dextran sulfate is a polysaccharide (dextran) with sulfate groups attached. The patent specifies a preferred molecular weight range of 5,000–100,000, used as the sodium salt.

Its properties: anti-inflammatory, anti-allergic, moisturizing, and protective against skin roughness. Alone it suppresses inflammation and edema; combined with escin's vascular stabilization, both mechanisms operate simultaneously.

Claim 1 (the minimum claimed scope):

• Dextran sulfate: 0.08–1.0% by weight
• Escin: 0.005–0.5% by weight

All Six Formulations, Transcribed

These are now public record.

Composition 4 is labeled "Eye Bag-Masking Gel" in the patent document itself. It sits at the low end of the claimed range — minimum effective concentration testing.

Composition 6 uses Eau de La Roche-Posay as part of the aqueous phase. L'Oréal acquired La Roche-Posay in 1989. By the time this patent was filed in 1999, the group's own brand ingredients were already integrated into research formulations. The design intent is visible at that level of detail.

25 Years Later: What the Market Did

The patent was filed in a pre-e-commerce, pre-ingredient-transparency era. In 2026:

Escin / Horse Chestnut

• Clarins (France) uses horse chestnut extract in its eye care line, citing capillary-stabilizing properties
• Givaudan (Switzerland, the world's largest fragrance and cosmetic ingredient supplier) sells escin as a commercial cosmetic active
• Multiple products indexed on INCIDecoder list it under "eye puffiness" and "vascular strengthening"

Dextran Sulfate

• L'Oréal's own ingredient library (lorealparisusa.com) lists Dextran as a skin-conditioning component
• INCIDecoder describes Dextran Sulfate as an anti-inflammatory for sensitive skin

The academic follow-through In 2018, a peer-reviewed paper published in the Journal of the European Academy of Dermatology and Venereology (Raynaud et al., PMID: 30233225) reported that dextran sulfate inhibits inflammatory and vascular responses implicated in rosacea. The study tested dextran sulfate in combination with three other ingredients — a different combination than the 1999 L'Oréal patent — but the underlying mechanism, dextran sulfate suppressing vascular inflammation, confirmed what Renault had documented nineteen years earlier.

What This Changes at the Shelf

A few practical take-aways from reading this patent:

What to look for in eye care

• Escin or Aesculus Hippocastanum Seed Extract (the INCI name for horse chestnut seed): signals capillary-stabilizing design intent, derived from the same lineage as this 1999 L'Oréal patent
• Dextran Sulfate or Sodium Dextran Sulfate: a polysaccharide anti-inflammatory now present in some sensitive-skin and eye-care formulations

Whether both appear together The patent's claim rests on synergy between the two. A product containing both may be closer to this design intent — though the actual concentrations remain invisible on a consumer label.

The regulatory framing The patent uses the word "treating." In cosmetic commerce — under Japan's Pharmaceutical and Medical Device Act, the U.S. FDA's OTC drug rules, or EU cosmetics regulation — no claim of treating rosacea or eliminating redness is permitted for a cosmetic product. Reading the patent tells you about the design logic. It does not tell you how a specific retail product has been formulated or what claims are legally supportable in your market.

Summary

A single researcher in a Paris lab spent 1999 documenting why combining two particular ingredients produced results neither achieved alone. The patent expired in 2020. The formulation logic is public. The ingredient market gradually adopted both components through independent channels, and the academic literature confirmed the mechanism nearly two decades after filing.

The three characters on a label — "Escin," "Dextran Sulfate" — now carry a traceable design history.

Sources

• US6562355B1 (Google Patents, public domain) — inventor: Béatrice Renault; assignee: Société L'Oréal S.A.; priority date: October 8, 1999; expiration: October 10, 2020
• EP1090629B1 (European counterpart patent, Google Patents)
• Raynaud JP, Thierry G, Soulage CO, Fromy B, Sigaudo-Roussel D. "Effects of dextran sulfate, 4-t-butylcyclohexanol, pongamia oil and hesperidin methyl chalcone on inflammatory and vascular responses implicated in rosacea." J Eur Acad Dermatol Venereol. 2019;33(3):566-574. PMID: 30233225
• Clarins Canada Ingredient Library — Horse Chestnut/Escin
• L'Oréal Paris Ingredient Library — Dextran
• INCIDecoder — Escin, Dextran Sulfate ingredient pages

This series is an archival exercise. The documents are old; the regulatory frameworks and formulation practices around any current product are separate questions. For decisions about health, skin conditions, or cosmetic choices, consult current sources and qualified professionals.